Institut Català de la Salut
[Llauradó A, Quintana M, Vidal-Taboada JM, Restrepo-Vera JL, Alemañ J, López-Diego V, Salvadó M, Sanchez-Tejerina D, Sotoca J, Juntas-Morales R] Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Gratacós-Viñola M, Raguer N] Servei de Neurofisiologia Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2024-05-13T08:09:14Z
2024-05-13T08:09:14Z
2024-04-08
Assessment; Chronic inflammatory demyelinating polyradiculoneuropathy
Evaluación; Polirradiculoneuropatía desmielinizante inflamatoria crónica
Avaluació; Poliradiculoneuropatia desmielinizant inflamatòria crònica
Background and Aims. Gait impairment is a common manifestation of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). However, clinicians lack an effective monitoring tool, as no gait test has been validated for CIDP. The aim of this study was to determine the usefulness of three tests in monitoring the clinical course of patients with CIDP: Timed Up and Go (TUG), 10-Meter Walk Test (10MWT), and 30-Second Chair Stand (30SCS). Methods. This is a prospective, single-center observational study. We included newly diagnosed CIDP patients starting treatment or relapsed CIDP patients requiring new treatment. We monitored the clinical course using CIDP-validated clinical scales and correlated changes in clinical status with the results of the gait tests. A ROC curve was developed, and we chose the cut-off point on each scale with the best specificity and sensitivity to detect change in clinical status. Results. A total of 20 patients have been recruited. The 3 tests show a statistical correlation with objective clinical improvement. In patients who have showed clinical improvement during the follow-up examination, a mean reduction of 4.8 seconds in TUG and 2.6 in 10MWT and a gain of 3 repetitions in 30SCS have been observed. The optimal cut-off points for each test were seconds, seconds, and repetition. The TUG test has the highest sensitivity (82.6%), and the 30SCS test has the highest specificity (100%) for detecting clinical improvement. Conclusions. The study found that the TUG and 30SCS tests could become effective tools for monitoring treatment response in CIDP patients.
Article
Published version
English
Marcadors bioquímics; Medicaments immunosupressors - Tractament; Trastorns de la marxa; Sistema nerviós - Malalties - Tractament; Malalties autoimmunitàries - Tractament; DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Polyradiculoneuropathy::Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; CHEMICALS AND DRUGS::Biological Factors::Biomarkers; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Immunologic Factors::Immunosuppressive Agents; DISEASES::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Neurologic Manifestations::Gait Disorders, Neurologic; ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::polirradiculoneuropatía::polirradiculoneuropatía desmielinizante inflamatoria crónica; COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores; COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::efectos fisiológicos de los fármacos::factores inmunitarios::inmunosupresores; ENFERMEDADES::afecciones patológicas, signos y síntomas::signos y síntomas::manifestaciones neurológicas::trastornos neurológicos de la marcha
Wiley
Hindawi
Acta Neurologica Scandinavica;2024
https://doi.org/10.1155/2024/7037704
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - VHIR [1655]